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A B S T R A C T
In 1889, Steven Paget postulated the theory that cancer cells require a permissive environment to grow. This
permissive environment is known as the tumor microenvironment (TME) and nowadays it is evident that the
TME is involved in the progression and response to therapy of solid cancer tumors. Triple-negative breast cancer
is one of the most lethal types of cancer for women worldwide and chemotherapy remains the standard treat-
ment for these patients. IMMUNEPOTENT CRP is a bovine dialyzable leukocyte extract with immunomodulatory
and antitumor properties. The combination of chemotherapy and IMMUNEPOTENT CRP improves clinical
parameters of breast cancer patients. In the current study, we aimed to evaluate the antitumor effect of dox-
orubicin/cyclophosphamide chemotherapy plus IMMUNEPOTENT CRP and its impact over the tumor micro-
environment in a triple-negative breast cancer murine model. We evaluated CD8+, CD4+, T regulatory cells,
memory T cells, myeloid-derived suppressor cells, CD71+, innate effector cells and molecules such as α-SMA,
VEGF, CTLA-4, PD-L1, Gal-3, IDO, IL-2, IFN-γ, IL-12, IL-6, MCP-1, and IL-10 as part of the components of the
TME. Doxorubicin/cyclophosphamide + IMMUNEPOTENT CRP decreased tumor volume, prolonged survival,
increased infiltrating and systemic CD8+ T cells and decreased tumor suppressor molecules (such as PD-L1, Gal-
3, and IL-10 among others).
In conclusion, we suggest that IMMUNEPOTENT CRP act as a modifier of the TME and the immune response,
potentiating or prolonging anti-tumor effects of doxorubicin/cyclophosphamide in a triple-negative breast
cancer murine model.
1. Introduction
Breast cancer is the most common type of cancer and the second
most lethal among women worldwide [1,2]. More than 1,000,000
women are diagnosed with breast cancer every year and 410,000 will
die from the disease [2]. Some subtypes of the disease, such as triple-
negative breast cancer, are particularly aggressive; the average overall
survival for patients with this form of cancer is 18 months [3]. These
tumors lack estrogen, progesterone, and the human epidermal growth
factor 2 receptors, rendering this type of cancer resistant to targeted
therapies [4].
Chemotherapy drugs remains the cornerstone treatment for most
types of cancer, reducing tumor burden by killing malignant cells;
however, drug resistance and toxic side effects lead to disease pro-
gression and metastasis [5].
In 1889, Steven Paget stated the “seed and soil” hypothesis where
he posited that fertile soil (the microenvironment) is essential for the
seed (cancer cells) to grow [6]. The tumor microenvironment (TME)
concept highlights the participation of immune system cells, extra-
cellular matrix, stromal cells, cancer cells, and signaling molecules in
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cancer development and response to oncological treatments [7]. Novel
approaches for the management of cancer patients should focus on
combined therapies that simultaneously target multiple components of
the tumor microenvironment and harness the immune response against
cancer cells [8].
IMMUNEPOTENT CRP (ICRP) is an immunomodulator that com-
prises a mixture of small molecules (> 12KDa) derived from bovine
spleen [9]. Our research group has demonstrated that ICRP has several
antitumor properties. It decreases inflammation and oxidative stress
through NF-ĸB pathway in murine macrophages in vitro [10], induces
apoptosis in breast cancer cells [11], decreases myelosuppression in
healthy mice treated with the chemotherapy agent 5-fluorouracil [9],
induces immunogenic cell death in a murine melanoma model [12],
and prevents implantation in a murine lymphoma model [13].
Based on its immunomodulatory properties, we hypothesized that
ICRP can be used to modify the tumor microenvironment and increase
systemic immunity, thus enhancing the antitumor effect of the doxor-
ubicin/cyclophosphamide treatment in a triple-negative breast cancer
murine model.
To assess our hypothesis we evaluated CD8, CD4, T reg, memory T
cells, myeloid derived suppressor cells (MDSC), CD71 (transferrin re-
ceptor), innate effectors cells (monocytes/macrophages, natural killer
cells, granulocytes and dendritic cells) and molecules such as α-smooth
muscle actin (SMA), vascular endothelial growth factor (VEGF), cyto-
toxic T cell ligand associated-4 (CTLA-4), programmed death cell li-
gand-1 (PDL-1), galectin 3 (Gal-3), indoleamine 2,3-dioxygenase (IDO),
IL-2, IFN-γ, IL-12, IL-6, MCP-1, and IL-10 as part of the components of
the tumor microenvironment of a 4T1 breast cancer model.
2. Methods
2.1. Cell line
4T1 murine breast cancer cell line was purchased from the
American Type Culture Collection (Manassas, Virginia, USA). Cells
were cultured in Dulbecco's Modified Eagle Medium (DMEM) supple-
mented with bovine fetal serum (10 % v/v) in a 37 °C and 5% CO2
atmosphere.
2.2. Animals
BALB/c female mice (6–8 weeks old) were provided by the bio-
terium of the Facultad de Ciencias Biológicas, UANL. Mice were kept in
12 h light/dark cycles with ad libitum water and food. All animal pro-
cedures were performed according to the official Mexican norm of
Animal Welfare NOM-033-SAG/ZOO-2014 and approved by the
internal Research and Animal Welfare Ethics Committee (CEIBA) of the
Facultad de Ciencias Biológicas, UANL.
2.3. Reagents
ICRP is an endotoxin-free dialyzed (> 12 KDa) bovine leukocyte
extract. One unit of ICRP has been defined as the product derived from
1 × 108 bovine spleen cells. Doxorubicin (Doxolem®) was purchased
from Teva Pharmaceuticals (México). Cyclophosphamide
(Hidrofosmin®) was purchased from Sanfer Laboratories (Mexico).
2.4. Air pouch induction, 4T1 cells inoculation, and animal treatments
Tumor cells were inoculated inside an air pouch. The air pouch
technique allows for a more accurate assessment by creating a con-
fined/defined environment in which the candidate drug is in direct
contact with the tumor [14]. The mice’s backs were shaved, and 5 mL of
sterile air was injected by subcutaneous route. Three days later, 3 ad-
ditional mL of sterile air was injected to avoid de-inflation [14].
4T1 viable cells (0.5 × 106) were injected inside the air pouch. Nine
days after inoculation, tumors reached approximately 100 mm3 and
mice were randomly divided into four experimental groups (n = 5): 1)
control group: without treatment, 2) Dox/Cyclo (doxorubicin/ cyclo-
phosphamide) group: a single dose of Dox (10 mg/kg, peritumoral
route) and Cyclo (100 mg/kg, i.p route), 3) ICRP group: 5 units of ICRP
daily for 9 days, and 3 more administrations every third day, by peri-
tumoral route and 4) Dox/Cyclo + ICRP: mice received both treatments
(Dox/Cyclo + ICRP) as previously described. Sacrifice was performed
30 days after 4T1 cell inoculation. Air pouch induction, 4T1 cell in-
oculation and treatment administration are depicted in Fig. 1.
Tumor width and length were measured every third day and tumor
volume was calculated with the formula: (width2 x length)/2 [15]. For
weight determination, tumors were removed (postmortem) and weighed
using a TE241S laboratory analytical balance (Sartorius, Goettingen,
Germany). Data are presented as the mean± standard deviation of five
animals per group.
For the animal survival experiment, five additional mice per ex-
perimental group were kept under observation for 60 days after 4T1 cell
inoculation. Mice were sacrificed if tumor volume reached 2000 mm3.
Survival was plotted in a Kaplan-Meier graph.
2.5. Immunohistochemistry
Tumors were dissected and fixed in formalin (10 % in PBS, pH 7.2)
for 24 h, followed by paraffin embedding. Tumor sections (3–5 μm)
were cut, deparaffinized and hydrated in a xylol-alcohol gradient.
Fig. 1. Air pouch induction, 4T1 cells inoculation and therapy administration.
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Tumor slides were incubated with 0.3 % H2O2 in Tris-buffered saline
(TBS) for 5 min and TBS plus 0.025 % Triton X-100 for 5 min. For
antigen retrieval, samples were incubated with sodium citrate buffer
(10 mM sodium citrate, 0.05 % Tween 20, pH 6.0) for 30 min at 60 °C.
Tumor slides were blocked with horse normal serum Vector
Laboratories, California, USA. Samples were incubated with the fol-
lowing primary antibodies: anti-CTLA-4 sc-376016, anti-PD1 sc-12767,
anti-PD-L1 364568, anti-IDO sc-137012, anti-Gal-3 sc-32790, anti-Ki-
67 381308, anti-cleaved-Caspase-3 ab214430, anti-VEGF sc-130289 or
anti-SMA A076031D at 4 °C for 24 h. All antibodies were used in a
1:1000 dilution. All antibodies were purchased from Santa Cruz
Biotechnology (California, USA) except for anti-Ki-67, anti-SMA, and
anti-PD-L1, which were purchased from US Biological (Massachusetts,
USA), and anti-cleaved-Caspase-3 which was purchased from Abcam
(Missouri, USA). Samples were incubated with biotinylated pan-specific
universal secondary antibody (Vector Laboratories, California, USA) for
10 min, counterstained with hematoxylin (Sigma Aldrich, Missouri,
USA) for 30 s, dehydrated in a xylol-alcohol gradient and mounted with
Entellan® (Merck Millipore, Darmstadt, Germany).
Digital micrographs were captured with a Zeiss Imager.Z1 micro-
scope (Zeiss, Germany) equipped with an AxioCam MRc5 camera
(Zeiss, Germany), and using the AxioVision V4.6 (Zeiss, Germany)
software.
DAB positive staining is evidenced by brown colored cells.
Quantification of staining intensity was performed using the image
processing software Fiji (ImageJ version 2.0) as described by Patera
et al. [16].
Briefly, the function color deconvolution (histological dyes digital
separation) was applied to the microphotographs; this provides three
independent digital images (H&E, DAB, and a complementary image),
after this stain-specific values for the optical density in each of the three
images can be determined. Mean grey values were collected from image
2 (DAB) and optical density was calculated with the formula optical
density = log(max grey intensity/mean grey intensity). Data are pre-
sented as the mean optical density± standard deviation of five sections
per tumor slide (five slides per group). The average mean optical den-
sity was compared between groups.
2.6. Splenocyte isolation
After the sacrifice, the spleens were aseptically removed from the
mice and placed on Petri dishes. Splenocytes were flushed out of the
spleen with sterile PBS (10 mL), briefly, PBS (10 mL) were injected
through each spleen, the PBS-cell suspension was collected, and this
step was repeated for 7–10 times or until the organ became pale. After
this, the spleen cells-PBS suspension was centrifuged at 1200 rpm for 10
min. To eliminate erythrocytes, the pellet was incubated with sterile
erythrocyte lysis solution (0.8 % NH4Cl, 0.1 mM EDTA, pH 7.2–7.6) in
mild agitation for 5 min and centrifuged at 1200 rpm for 10 min.
Splenocytes were resuspended in DMEM cell culture media. Cell via-
bility and count were determined by the trypan blue exclusion tech-
nique. This procedure can yield from 5 × 106 to 13 × 106 viable
splenocytes. Differences could be attributable to tumor properties
(splenomegaly) or treatment (chemotherapy reduces spleen size).
2.7. Ex vivo splenocyte/4T1 co-culture
Cells (5 × 104 4T1) were seeded in 24 well plates at 37 °C and 5%
CO2 atmosphere for 24 h. Splenocytes from mice without tumor or
control tumor-bearing mice (untreated) or treated with Dox/Cyclo,
ICRP or Dox/Cyclo + ICRP were added in a 1:1, 1:10 and 1:25 targe-
t:effector cell ratio for 24 h at 37 °C and 5% CO2 atmosphere. 4T1 cells
were detached with Accutase (Sigma Aldrich, Missouri, USA). 4T1 cell
death was analyzed with 7AAD staining by flow cytometry with a BD
Accuri™ C6 flow cytometer (BD Biosciences, California, USA), excluding
splenocytes by cell size and granularity. Data are presented as the
mean± standard deviation of five animals per group.
2.8. Cytokines determination
Cytokines were analyzed in serum and tumor tissue at the end of the
experiment (30 days after tumor cell inoculation). For tumor tissue
samples, tumors were sliced and incubated at 4 °C with lysis buffer (150
mM sodium chloride, 1% triton 100-X, 50 mM Tris, Halt™ Protease
Inhibitor Cocktail, pH 8.0) in mild agitation for 60 min. Then lysed
tumors were centrifuged for 20 min at 12,000 rpm and the supernatant
was collected for further analysis. For serum, peripheral blood was
centrifuged at 3600 rpm for 10 min at 4 °C in an Eppendorf 5804R
refrigerated centrifuge (Hamburg, Germany).
Cytokine levels were determined with the BD Cytometric Bead
Array (CBA) Mouse Inflammation Kit (BD Horizon, California, USA)
according to the manufacturer instructions. Briefly, 50 μL of Mouse
Inflammation capture beads were mixed with 50 μL of each sample and
50 μL Mouse Inflammation PE Detection Reagent. Assay tubes were
incubated for 2 h in the dark at room temperature. After this, 1 mL of
wash buffer was added to the assay tubes and centrifuged for 5 min at
1200 rpm. The supernatant was discarded, and the pellet was re-sus-
pended in 100 μL of wash buffer. Events were acquired in a BD Accuri™
C6 flow cytometer (BD Horizon, California, USA). Cytokine levels were
analyzed with the CFlow plus software (BD Biosciences, California,
USA). Data are presented as the mean± standard deviation of five
animals per group.
2.9. Leukocyte isolation
Tumors were sliced and incubated with 0.1 mg/mL of Liberase™ TL
(Roche, Mannheim, Germany) at 37 °C for 30 min in mild agitation. The
resulting cell suspension was rinsed with PBS. Leukocytes from this
tumor cell suspension or from peripheral blood were purified by gra-
dient density separation with Polymorphoprep™ reagent (Axis Shield,
Dundee, United Kingdom) according to the manufacturer instructions.
2.10. Leukocyte immunophenotyping
Leukocytes were stained with the following fluorophore labelled
antibodies: anti-mouse CD3 FITC 555274, anti-mouse CD8 PE 553033,
anti-mouse CD4 APC 553051, anti-mouse CD44 PE (51-9007324) anti-
mouse CD62 L APC (5-9007326), anti-mouse CD45 PerCP 557235, anti-
mouse CD71 FITC 553266, anti-mouse CD16/CD32 APC 558636, anti-
mouse CD25 PE 12-0251-81, anti-mouse FOXP3 PE-Cy5 15-5773-80A
and anti-mouse Ly6G/C 553128 all manufactured by BD Biosciences
California, USA.
For FOXP3 staining, cells were fixed with formaldehyde (4% v/v in
PBS) for 1 min and then permeabilized with methanol (90 % in PBS) for
30 min on an ice water bath, washed twice with albumin (0.5 % p/v in
PBS) and re-suspended in PBS.
Cells were incubated with the antibodies for 30 min in the dark at
room temperature, then centrifuged twice with albumin (0.5 % p/v in
PBS) for 5 min at 1200 rpm and resuspended in PBS (100 μL). Events
were acquired in a BD Accuri™ C6 flow cytometer (BD Horizon,
California, USA). Data are presented as the mean± standard deviation
of five animals per group.
2.11. Hematoxylin and eosin staining
Mice brain, lungs, heart, liver, and spleen were removed and fixed
in formalin (10 % in PBS, pH 7.2) for 24 h, followed by paraffin em-
bedding. Tumor sections (3–5 μm) were cut, deparaffinized and hy-
drated in a xylol-alcohol gradient. Organ tissues were stained with
Mayer hematoxylin solution for 8 min and counterstained with eosin-
phloxine B solution for 45 s, dehydrated in a xylol-alcohol gradient and
mounted with Entellan® (Merck Millipore, Darmstadt, Germany).
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2.12. Blood and serum analyses
After sacrifice, blood from all experimental groups was collected in
microtainer collection tubes with K2EDTA for blood analysis and li-
thium-heparin and gel for serum analysis. Hematological parameters
were determined with the Sysmex XS 1000 analyzer (Sysmex, Kobe,
Japan) and biochemical parameters with the COBAS INTEGRA® 400
plus analyzer (Roche, Mannheim, Germany). Data are presented as the
mean± standard deviation of five animals per group.
2.13. Statistical analysis
Statistical differences between groups were analyzed using ANOVA
followed by the Tukey post-hoc test or Mantle-Cox test (for survival
analysis). Differences between groups were considered significant at a
p-value ≤ 0.05. Statistical analyses were performed with the GraphPad
Prism 7.0 (GraphPad Software, Inc., San Diego, CA).
3. Results
3.1. Dox/Cyclo + ICRP decreased tumor volume and weight and increased
animal survival in 4T1-tumor-bearing mice
All treatments significantly reduced (p≤ 0.05) tumor volume (since
day 21) and weight (day 30) (p ≤ 0.05), as compared to the control
group (Fig. 2a and b). There was no statistical difference between tumor
volumes and weight for the Dox/Cyclo and ICRP treated groups. On the
other hand, there was a significant decrease in tumor volume and
weight (p ≤ 0.05) after Dox/Cyclo + ICRP treatment compared with
the remaining treatments (Fig. 2a and b).
All treatments significantly prolonged (p ≤ 0.001) the survival of
tumor-bearing mice compared to the control group (Fig. 2c).
3.2. Dox/Cyclo + ICRP decreased Ki-67 and increased caspase 3
All treatments significantly decreased (p ≤ 0.05) Ki-67 expression
as compared to the control group. There was no significant difference (p
≤ 0.05) of Ki-67 expression between treated groups: Dox/Cyclo, ICRP
and Dox/Cyclo + ICRP (Fig. 3a and b). Dox/Cyclo + ICRP treatment
significantly increased (p ≤ 0.05) caspase-3 expression as compared to
the control and Dox/Cyclo groups. There is no statistical difference (p
≤ 0.05) between caspase-3 expression of ICRP and the other groups
(Fig. 3a and b).
3.3. Dox/Cyclo + ICRP decreased CTLA-4 and PD-L1
Dox/Cyclo significantly increased (p ≤ 0.05) CTLA-4 expression as
compared to the control and Dox/Cyclo + ICRP groups. There was no
significant difference (p ≤ 0.05) between CTLA-4 expression in the
ICRP group as compared to the others (Fig. 4a and d).
There was no significant difference (p ≤ 0.05) in PD1 expression
between groups (Fig. 4b and d).
PD-L1 expression significantly decreased (p≤ 0.05) in the ICRP and
Dox/Cyclo + ICRP treated groups as compared to the control and Dox/
Cyclo groups (Fig. 4c and d).
3.4. Dox/Cyclo + ICRP decreased suppressor molecule Gal-3
ICRP significantly decreased (p ≤ 0.05) IDO expression in tumor
tissue as compared to the control and Dox/Cyclo groups (Fig. 5a and b).
There was no significant difference (p ≤ 0.05) between IDO expression
in the Dox/Cyclo + ICRP group as compared to the other groups
(Fig. 5a and b).
ICRP and Dox/Cyclo + ICRP treatments significantly decreased (p
≤ 0.05) Gal-3 expression in the tumor as compared to the control and
Dox/Cyclo groups (Fig. 5c and d).
3.5. Dox/Cyclo + ICRP decreased VEGF and α-SMA
Dox/Cyclo + ICRP significantly decreased (p ≤ 0.05) VEGF ex-
pression as compared to the control, Dox/Cyclo and ICRP groups
(Fig. 6a and b).
ICRP and Dox/Cyclo + ICRP significantly decreased (p ≤ 0.05) α-
SMA expression as compared to the control and Dox/Cyclo groups
(Fig. 6c and d).
Fig. 2. Tumor volume (a), tumor weight (b)
and animal survival (c). (a) Tumor volume
(mm3) was measured every third day since day
9 post inoculation. (b) Thirty days after 4T1
cell inoculation, 5 mice of each experimental
group were sacrificed, and the tumor mass was
removed and weighted. All data shown re-
presents the mean± SD. Statistical sig-
nificance (p ≤ 0.05) was determined by one-
way ANOVA and the Tukey post hoc test.
There is no statistical difference between bars
labeled with the same letter in the graph (a,b,c).
(c) Five additional mice per group, were kept
for 60 days to plot Kaplan Meier survival
curves. Statistical difference between experi-
mental groups (*p ≤ 0.01) was determined
with the log-rank test (Mantel-Cox).
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3.6. ICRP partially restores splenocytes cytotoxic activity in tumor-bearing
mice treated with Dox/Cyclo
Viable splenocytes were obtained from mice without tumor and
from untreated tumor-bearing mice (control) or treated with Dox/
Cyclo, ICRP or Dox/Cyclo + ICRP. Splenocytes (effector cells) were co-
cultured with 4T1 cells (target cells) in a 1:1, 1:10 and 1:25
target:effector cell ratio for 24 h.
In the 1:1 ratio, the cytotoxic effect from splenocytes over 4T1 cells
was 10 % or less for all tested groups (Fig. 7c).
In the 1:10 ratio, the cytotoxic effect of splenocytes from untreated
(23.53 %), ICRP (22.8 %), or Dox/Cyclo + ICRP (21.6 %) tumor-
bearing mice was significantly higher (p ≤ 0.05) than the effect of
splenocytes in mice without tumor (1.17 %) and tumor-bearing mice
Fig. 3. Immunohistochemical staining and
optical density (OD) value of Ki-67 and
Caspase-3 in tumor tissue. (a) Representative
micrograph of Ki-67 immunostaining visua-
lized with DAB and counterstained with he-
matoxylin and (b) optical density (mean gray
value) obtained by color deconvolution ana-
lysis. (c) Representative micrograph of cleaved
caspase-3 immunostaining visualized with
DAB and counterstained with hematoxylin and
(d) optical density (mean gray value) obtained
by color deconvolution analysis.
Optical density graph bars (b and d) represent
the mean± SD (n = 5). Statistical significance
(p ≤ 0.05) was determined by one-way
ANOVA and the Tukey post hoc test. There is
no statistical difference between bars labeled
with the same letter in the graph (a,b).
Fig. 4. Immunohistochemical staining and
optical density (OD) value of CTLA-4, PD1, and
PD-L1 in tumor tissue. Representative micro-
graph of CTLA-4 (a), PD1 (b), and PD-L1 (c)
immunostaining visualized with DAB and
counterstained with hematoxylin. (d) Optical
density (mean gray value) obtained by color
deconvolution analysis. Optical density graph
bars represent the mean± SD (n = 5).
Statistical significance (p ≤ 0.05) was de-
termined by one-way ANOVA and the Tukey
post hoc test. There is no statistical difference
between bars labeled with the same letter in
the graph (a,b).
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treated with Dox/Cyclo (5.83 %). There was no statistical difference (p
≤ 0.05) between the cytotoxic effect of splenocytes from mice without
tumor and tumor-bearing mice treated with Dox/Cyclo (Fig. 7c).
In the 1:25 ratio, the cytotoxic effect of splenocytes from untreated
(67.03 %), ICRP (56.2 %), or Dox/Cyclo + ICRP (41.07 %) tumor-
bearing mice was significantly higher (p ≤ 0.05) than the effect of
splenocytes of mice without tumor (12.6 %) and tumor-bearing mice
treated with Dox/Cyclo (11.97 %). The cytotoxic effect of splenocytes
Fig. 5. Immunohistochemical staining and
optical density (OD) value of IDO and Gal-3 in
tumor tissue. (a) Representative micrograph of
IDO immunostaining visualized with DAB and
counterstained with hematoxylin and (b) op-
tical density (mean gray value) obtained by
color deconvolution analysis. (c)
Representative micrograph of galectin 3 im-
munostaining visualized with DAB and coun-
terstained with hematoxylin and (d) optical
density (mean gray value) obtained by color
deconvolution analysis. Optical density graph
bars (b and d) represent the mean± SD (n =
5). Statistical significance (p ≤ 0.05) was de-
termined by one-way ANOVA and the Tukey
post hoc test. There is no statistical difference
between bars labeled with the same letter in
the graph (a,b).
Fig. 6. Immunohistochemical staining and
optical density (OD) value of VEGF and α-SMA
in tumor tissue. (a) Representative micrograph
of VEGF immunostaining visualized with DAB
and counterstained with hematoxylin and (b)
optical density (mean gray value) obtained by
color deconvolution analysis. (c)
Representative micrograph of α-SMA im-
munostaining visualized with DAB and coun-
terstained with hematoxylin and (d) optical
density (mean gray value) obtained by color
deconvolution analysis. Optical density graph
bars (b and d) represent the mean± SD (n =
5). Statistical significance (p ≤ 0.05) was de-
termined by one-way ANOVA and the Tukey
post hoc test. There is no statistical difference
between bars labeled with the same letter in
the graph (a,b).
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from untreated mice or mice treated with ICRP was significantly higher
(p ≤ 0.05) than the cytotoxic effect of splenocytes from Dox/Cyclo +
ICRP treated mice (Fig. 7b and c).
3.7. Dox/Cyclo + ICRP increased TNF-α, IFN-γ, IL-12, IL-6, MCP-1 and
IL-10 serum levels
All treatments significantly increased (p ≤ 0.05) IFN-γ, IL-12, IL-6,
IL-10 and MCP-1 in sera as compared to the control. Dox/Cyclo + ICRP
significantly increased (p ≤ 0.05) TNF-α (70.27 pg/mL) when com-
pared to the control (41.34 pg/mL). There was no significant difference
(p ≤ 0.05) for TNF-α, IFN-γ and IL-6 expression between treated
groups, however, significant difference (p ≤ 0.05) was found for IL-12
and IL-10 (Fig. 8).
3.8. Dox/Cyclo + ICRP increased IFN-γ levels in tumor tissue
At the level of tumor microenvironment, Dox/Cyclo + ICRP sig-
nificantly increased (p ≤ 0.05) TNF-α, IFN-γ and IL-6 levels and sig-
nificantly decreased (p ≤ 0.05) IL-10 as compared to the control group
(Fig. 9).
ICRP significantly increased (p ≤ 0.05) IFN-γ (2.54 pg/mL) and IL-
12 (61.85 pg/mL), and significantly decreased (p ≤ 0.05) IL-6 (15.88
pg/mL), IL-10 (86.08 pg/mL) and MCP-1 (139.67 pg/mL) cytokines,
without affecting TNF-α (14.06 pg/mL), when compared to the control
(Fig. 9).
Dox/Cyclo treatment did not affect the evaluated cytokines as
compared to the control, except for IL-6 (10.33 pg/mL), that sig-
nificantly decreased (p ≤ 0.05) (Fig. 9).
3.9. Dox/Cyclo + ICRP increased cytotoxic and memory T cells and
decreased T regulatory lymphocytes and myeloid suppressor cells in
peripheral blood of 4T1 tumor-bearing mice
Dox/Cyclo significantly increased (p ≤ 0.05) CD8 (51 %) and T reg
cells (73 %) and significantly decreased (p ≤ 0.05) innate effector cells
(9.35 %) without affecting CD4 (58.4 %), memory T cells (32.65 %),
CD71 (28.05 %), and MDSC (29 %) populations as compared to the
control.
ICRP significantly increased (p ≤ 0.05) CD8 (96.6 %), memory T
cells (71.95 %), innate effector cells (45.7 %) and decreased sig-
nificantly (p ≤ 0.05) CD4 (16.95 %) without affecting CD71 (41.24 %),
T reg (29.75 %) and MDSC (24.05 %) as compared to the control.
Dox/Cyclo + ICRP significantly increased (p ≤ 0.05) CD8 (66.95
%), memory T cells (71.65 %), and T reg (46.9 %) and significantly
decreased (p ≤ 0.05) CD4 (33.05 %), MDSC (13.2 %) without affecting
CD71 (13.25 %) and innate effector cells (31.2 %) as compared to the
control.
When compared between treated groups, ICRP, as monotherapy and
combined, significantly increased (p ≤ 0.05) CD8 (96.6 % and 66.95
%) and memory T cells (71.95 % and 71.54 %) compared to the Dox/
Cyclo group (51 % and 32.65 %, respectively). Also, ICRP, as mono-
therapy and combined, decreased T reg (29.75 % and 46.9 %, respec-
tively) as compared with Dox/Cyclo (73 %).
Fig. 7. Ex-vivo cytotoxic effect of splenocytes over 4T1 cells. Splenocytes from mice without tumor and untreated 4T1 tumor-bearing mice or treated with: Dox/
Cyclo, ICRP, or Dox/Cyclo + ICRP were co-cultured with 5 × 104 4T1 cells for 24 h. The figure shows representative dot plot of the FSC (size) and SSC (granularity)
gating strategy to discriminate splenocyte (effector cells) and 4T1 (target cells) (a); FSC dot plot and cell count histogram versus 7AAD staining for the 1:25 target/
effector cell ratio (b); and cell death (%) graph bars representing 7AAD positive staining in the target/effector cell ratio 1:1, 1:10, and 1:25. Graph bar values
represent mean ranges± SD (p ≤ 0.05) (n = 5). Statistical significance was determined by the Tukey post hoc test. There is no statistical difference between bars
labeled with the same letter in the graph (a,b,c,d).
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Dox/Cyclo + ICRP significantly decreased (p ≤ 0.05) CD71 (13.25
%) as compared to the Dox/Cyclo group (28.05 %).
ICRP significantly increased (p ≤ 0.05) innate effector cells (45.7
%) as compared to the other groups (Fig. 10).
3.10. Dox/Cyclo + ICRP increased cytotoxic and memory T cells, and
innate effector cells in tumor tissue
Dox/Cyclo + ICRP significantly increased (p ≤ 0.05) CD8 cells
(93.5 %) as compared to all other groups.
Dox/Cyclo + ICRP significantly increased (p ≤ 0.05) memory T
cells (85.1 %) as compared to the control group (32.65 %) and sig-
nificantly decreased (p≤ 0.05) T regulatory cells (14.2 %) as compared
to the control group (52.95 %).
ICRP and Dox/Cyclo + ICRP significantly increased (p ≤ 0.05)
innate effector cells (45.35 % and 49.8 %, respectively) as compared to
control (12.75 %) and Dox/Cyclo (27.85 %) groups.
ICRP and Dox/Cyclo + ICRP significantly decreased (p ≤ 0.05)
MDSC (28.3 % and 3.2 %, respectively) as compared to the Dox/Cyclo
group (59.9 %) (Fig. 11).
3.11. ICRP and Dox/Cyclo + ICRP did not affect tissue histology of spleen,
liver, kidney, brain, lung and heart of 4T1 tumor-bearing mice
Hematoxylin and eosin (H&E) stain revealed no noticeable damage
or inflammatory lesions in major organs (spleen, liver, kidney, brain,
lung and heart) for any experimental group (Fig. 12).
3.12. ICRP and Dox/Cyclo + ICRP improved hematological and
biochemical parameters in 4T1 tumor-bearing mice
Hematological parameters were in the standard range, except for
leukocytosis in the control (15.21± 1.62 109 x L) (Table 1). Serum
biochemical parameters were also in the standard range, except for
aspartate aminotransferase and alanine aminotransferase which in-
creased in the control (276.5± 20 UI/L and 187±25 U/L,
Fig. 8. TNF-α, IFN-γ, IL-12, IL-6, IL-10, and
MCP-1 levels in serum. 30 days after 4T1 cell
inoculation, serum was collected from un-
treated 4T1 tumor-bearing mice (control) or
treated with: Dox/Cyclo, ICRP, or Dox/Cyclo
+ ICRP. Graph bars represent cytokine levels
determined by flow cytometry analysis with
the CBA mouse inflammation kit. Data is ex-
pressed as mean values± SD (p ≤ 0.05) (n =
5). Statistical significance was determined by
the Tukey post hoc test. There is no statistical
difference between bars labeled with the same
letter in each graph (a,b,c,d).
Fig. 9. TNF-α, IFN-γ, IL-12, IL-6, IL-10, and
MCP-1 levels in tumor tissue. 30 days after 4T1
cell inoculation, untreated 4T1 tumor-bearing
mice (control) or treated with: Dox/Cyclo,
ICRP, or Dox/Cyclo + ICRP were sacrificed
and had their tumors removed. Tumors were
disaggregated with Liberase™ TL and cen-
trifuged to obtain the supernatant. Graph bars
represent cytokine levels determined by flow
cytometry analysis with the CBA mouse in-
flammation kit. Data is expressed as mean
values± SD (p ≤ 0.05) (n = 5). Statistical
significance was determined by the Tukey post
hoc test. There is no statistical difference be-
tween bars labeled with the same letter in each
graph (a,b,c,d).
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respectively) and their levels were partially restored in the Dox/Cyclo
(97± 1.41 UI/L and 59.5±0.71 U/L, respectively), ICRP (152±59.4
UI/L and 90.5±40.31 U/L, respectively) and Dox/Cyclo + ICRP
(98± 2.83 UI/L and 56±8.49 U/L, respectively) groups (Table 2).
4. Discussion
Our results showed that all treatments delayed tumor growth and
increased mice survival; however, the combined therapy was more ef-
fective than Dox/Cyclo or ICRP alone. Although chemotherapy induces
systemic immunosuppression, it can also work with immunotherapies
by decreasing tumor-induced local immunosuppression through cancer
cell debulking, potentiating the antitumor effect of combined therapies
[17].
All treatments decreased Ki-67 expression, but only ICRP and Dox/
Cyclo + ICRP treatments increased cleaved caspase-3 expression, cor-
relating with the tumor volume reduction and survival, suggesting that
tumor proliferation is reduced. Ki-67 is a cell proliferation marker, and
caspase-3 is an enzyme that activates (cleaved) when cells undergo
apoptosis [18]. Cancer cells rely on increased proliferation rate and
apoptosis resistance to stay alive; drugs or treatments that decrease cell
proliferation and restore apoptosis have a potential antitumor effect
Fig. 10. Immunophenotype of peripheral blood leukocytes. Blood was taken from untreated 4T1 tumor-bearing mice (control) or treated with: Dox/Cyclo, ICRP, or
Dox/Cyclo + ICRP 30 days after 4T1 cell inoculation. The figure shows (a) histograms representing the percentage of CD8, CD4, memory T cells, CD71 leukocytes
cells, innate effector cells, T reg and MDSC versus cell count in the Y axis. And (b) bar graphs representing the mean percentage per group (n = 5)± SD (p≤ 0.05) for
each phenotype, as determined by flow cytometry. Statistical significance was determined by the Tukey post hoc test. There is no statistical difference between bars
labeled with the same letter in each graph (a,b,c,d).
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[19].
Furthermore, the Dox/Cyclo and ICRP combination decreased VEGF
and α-SMA expression in the tumor, both of which are desirable targets
for cancer therapy [20]. VEGF is a key regulatory of angiogenesis se-
creted by cancer-associated fibroblasts (CAFs) [20]. α-SMA is used as a
marker for CAFs [20]. Tumors require the formation of new blood
vessels, mainly induced by CAFs, to obtain oxygen and nutrients [21].
ICRP simultaneously decreased PD-L1, IDO, and Gal-3; however,
there was no difference in CTLA-4 and PD1 expression in response to
any of the treatments with ICRP. The immune system plays a major role
in treatment response and patient outcome; immune cells eliminate
drug-resistant cancer cells, and continue to eliminate any emerging
tumor cells, even after therapy (immunological memory) [22]. Sup-
pressor immune checkpoints (CTLA-4, PD1, and PD-L1) and molecules
(IDO and Gal-3) are overexpressed within the tumor microenvironment,
impairing the T cell response and correlating with poor patient outcome
[23]. There are previous reports of compounds that modulate immune
checkpoints and suppressor molecules, for example, curcumin, a
Fig. 11. Immunophenotype of tumor tissue leukocytes. 30 days after 4T1 cell inoculation, untreated 4T1 tumor-bearing mice (control) or treated with: Dox/Cyclo,
ICRP, or Dox/Cyclo + ICRP were sacrificed and had their tumors removed. Tumors were disaggregated with Liberase™ TL and leukocytes were isolated by density
gradient separation with Polymorphprep™. The figure shows (a) histograms representing the percentage of CD8, CD4, memory T cells, CD71 leukocytes cells, innate
effector cells, T reg and MDSC versus cell count in the Y axis. And (b) bar graphs representing the mean percentage per group (n = 5)± SD (p ≤ 0.05) for each
phenotype, as determined by flow cytometry. Statistical significance was determined by the Tukey post hoc test. There is no statistical difference between bars
labeled with the same letter in each graph (a,b,c).
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polyphenol derived from the rhizome of Curcuma longa, decreases IDO
levels in LPS stimulated dendritic cells [24]. Another case is apigenin,
which suppresses PD-L1 expression in melanoma and host dendritic
cells to elicit synergistic therapeutic effects [25]. CTLA-4 and PD1 are T
cell surface receptors that block T cell receptor (TCR) complex activa-
tion signals [26]. CTLA-4 and PD1 molecules are mainly expressed by
activated T lymphocytes and T reg cells [27], whereas PD-L1, Gal-3 and
IDO are expressed not only by T cells, but also by antigen-presenting
cells, cancer and stromal cells [28–30], suggesting that ICRP decreases
suppression molecules in one or more of these cell types, thus mod-
ifying the tumor microenvironment and peripheral immunity to gen-
erate an antitumor T cell response.
In order to assess the immunological state of the mice included in
this study, we evaluated cytokine profiles and leukocyte markers. All
treatments increased systemic IFN-γ, IL-12, and MCP-1, correlating
with a T cell 1 (CD8+ T cells that secrete IFN-γ) type immune response.
IL-6 and IL-10 serum levels were also increased by all treatments. IL-6 is
a pleiotropic pro-inflammatory cytokine associated with inflammation
and tumor growth. Despite this, in TNBC models the increase of IL-6
correlates with tumor reduction [31]. IL-10 is classified as an immune-
suppressor cytokine, however, it is essential to reduce tumor-associated
inflammation, and it is positively correlated with disease-free survival
in breast cancer patients [31].
Within the tumor tissue, pro-inflammatory cytokines levels were
Fig. 12. Representative micrographs of liver, kidney, spleen, heart, lung and brain. Untreated 4T1 tumor-bearing mice or treated with: Dox/Cyclo, ICRP, or Dox/
Cyclo + ICRP were sacrificed 30 days after tumor induction. Liver, kidney, spleen, heart, lung and brain were collected and fixed in formaldehyde (10 % v/v),
embedded in paraffin, and 5 μm slices were stained with hematoxylin and eosin. Photomicrographs were taken at a magnification x400.
Table 1
Hematological parameters of tumor-bearing mice.
Control Dox/Cyclo ICRP Dox/Cyclo + ICRP Normal range
Neutrophils (%) 39.5± 12.02 42.00± 16.97 37.50± 9.19 44.50± 19.09 35.0–75.0
Lymphocytes (%) 52± 8.49 44.50± 9.19 52.00± 11.31 45.5± 7.68 25.0–50.0
Monocytes (%) 7.5±3.54 6.5± 3.36 7.50±3.54 7.00± 0.01 2.0–10.0
Eosinophils (%) 1± 0.5 7.00±1.41 3.00±1.41 3.00± 1.41 1.0–4.0
Total white blood cell count (109/L) 15.21± 1.62a 6.49±0.18b 9.08±4.24c 6.11± 3.54b 4.00–10.00
Hematocrit (%) 33.95± 2.33 40.45± 0.49 42.05± 3.61 39.15± 2.19 40.0–54.0
Hemoglobin (g/dL) 10.95± 0.92 12.70± 0.5 13.10± 1.27 12.05± 0.64 14.0–17.5
After 4T1 cell inoculation (day 30), peripheral blood was collected from untreated 4T1 tumor-bearing mice (control) or treated with: Dox/Cyclo, ICRP, or Dox/Cyclo
+ ICRP. Hematological parameters were analyzed with the hematology analyzer Sysmex XS 1000. Values are presented as mean±SD (p ≤ 0.05) (n = 5). Statistical
significance was determined by the Tukey post hoc test. There is no statistical difference between data labeled with the same letter (a,b,c).
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affected in a treatment-dependent manner. In our study, it is interesting
to note that the use of ICRP or Dox/Cyclo as monotherapies correlate
with the tumor reduction and decrease of IL-6 in the TME. However, a
better response was obtained by the combined treatment of Dox/Cyclo
+ ICRP, resulting in an increase of pro-inflammatory cytokines.
The combination treatment increased CD8+ and memory T cells
both at systemic and TME levels. CD8+ T cells are associated with
immune surveillance and good patient prognosis [8]. CD8+ T cells
maintained their effector phenotype, evidenced by tumor reduction,
production of TNF-α and IFN-γ, and increase of memory T cells, sug-
gesting that the treatment with ICRP alone or combined elicited an anti-
tumor immune response.
The Dox/Cyclo treatment increased MDSC within the TME (corre-
lating with increased IDO levels) and peripheral blood T reg cells. It is
worth mentioning that, although low-dose cyclophosphamide is used to
decrease T reg cells, we administered the therapeutic dose [32]; the
therapeutic dose of cyclophosphamide and doxorubicin increases MDSC
in cancer patients [33]. T reg and MDSC induce local and systemic
immune tolerance via IDO production, impairing antigen presentation
and therefore enabling the immune escape and metastasis of breast
cancer cells [34].
Our findings indicate that Dox/Cyclo + ICRP therapy administra-
tion elicited a strong immune response against breast cancer cells. To
corroborate this, we performed the splenocyte/4T1 cells co-culture. We
observed a higher cytotoxic response with splenocytes from the control
group, indicating the capacity of peripheral immunity to recognize and
eliminate 4T1, however not at TME level, as observed by tumor pro-
gression. Splenocytes from Dox/Cyclo group did not eliminated 4T1
cancer cells, suggesting an impaired cytotoxic activity at systemic level.
Myelosuppression is strongly associated with Dox/Cyclo regimens and
drug-induced myelosuppression impairs tumor immunity [35]. On the
other hand, the cytotoxic activity of splenocytes was partially recovered
by the combination of Dox/Cyclo with ICRP.
The putative mechanism of action by which ICRP increases Dox/
Cyclo anti-tumor effect is outlined below. The combination of Dox/
Cyclo + ICRP induced cancer cell mitosis arrest and death, as evi-
denced by Ki-67 decrease and cleaved caspase 3 increase [36]. In the
TME cancer cells produce various immunosuppressive molecules, in-
cluding IL-10, PD-L1 and Gal-3 [37]. Cancer cell cytoreduction in ad-
dition to the immunomodulatory properties of ICRP [38] allowed the
remodeling of non-cancer elements within the tumor toward an in-
crease of CD8+ and memory T cells phenotype and a decrease of T reg
cells and CAFs associated factors VEGF and α-SMA [20].
Coupled with this process there was a release of TNF-α, IFN-γ and
IL-6 that correlate with the recruitment of T cells, macrophages, and
dendritic cells [39,40,41,42,43]. These cells orchestrate the induction
and effector phase of tumor-specific immunity, as demonstrated with
the co-culture of splenocytes with 4T1 cells that resulted in cancer-
specific cell death.
We suggest that further experiments with immunodeficient mice (T,
B, natural killer, and macrophages) should be performed to clarify the
role of ICRP as a modifier of the immune response at systemic and in-
tratumoral levels. We would also like to mention, that despite all
treatments decreased tumor volume and increased mice survival, it
would be of interest to evaluate the efficacy of achieving tumor re-
gression in other breast cancer models.
Finally, we evaluated major organs (brain, lungs, heart, liver, and
spleen) and no histopathological changes were observed in treated
mice. It is worth mentioning that a major concern with combined
therapies for cancer is the adverse side effects.
Hematological and biochemical parameters are also important di-
agnostic tools for disease monitoring and patient wellbeing [44]. There
was a mild leukocytosis in the control group and elevated levels of
aspartate aminotransferase and alanine aminotransferase in all groups,
with the control group being the highest. However, no damage was
observed in the liver histological analysis, therefore the mild leukocy-
tosis and elevated enzymes seem to indicate a chronic inflammation
process (tumor itself), that did not affect performance and life quality of
treated mice. These results show that our combined treatment has good
biocompatibility.
In conclusion, we suggest that ICRP modifies the TME and immune
response potentiating or prolonging the anti-tumor activity of Dox/
Cyclo chemotherapy in a TNBC murine model. Furthermore, ICRP can
serve as a basis for therapies that target multiple components of the
TME and immune response against cancer cells.
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